Effect of Hydrocotarnine on Cytochrome P450 and P-glycoprotein
Authors:
- Yu KubotaYKYu Kubota
- Takahiro TodaTTTakahiro Toda
- Satoshi SutoSSSatoshi Suto
- Nobutomo IkarashiNINobutomo Ikarashi
- Kiyoshi SugiyamaKSKiyoshi Sugiyama
- 1 January 2009
- journal article
- Published by Japanese Society for the Study of Xenobiotics in Drug Metabolism and Pharmacokinetics
- Vol. 24 (1) , 108-113
Abstract
The injectable form of oxycodone contains hydrocotarnine that is supposed to potentiate the analgesic effect of oxycodone with unknown mechanism(s). In this study, the effects of hydrocotarnine on the cytochrome P450 (CYP) and P-glycoprotein (P-gp) were investigated. Hydrocotarnine did not induce a significant change in the metabolic activities of CYP2C9, 2C19, and 2E1 in an in vitro study using human CYP recombinants. Although weak inhibitory effects were observed on CYP3A4 and 2D6, these interactions did not seem to be clinically relevant. Hydrocotarnine also did not cause a significant change in the ATPase activity of human P-gp membranes, suggesting that it is not an inhibitor of P-gp. Furthermore, mice were intraperitoneally injected with hydrocotarnine for 14 days and the mRNA levels of major CYP isozymes and P-gp in the liver and small intestine were determined by real-time RT-PCR. As a result, none of the mRNAs investigated showed a significant change in their levels by hydrocotarnine treatment. In conclusion, it is unlikely that the potentiation of oxycodone effect by hydrocotarnine involves its effect on CYP and P-gp. The findings also demonstrate that hydrocotarnine is unlikely to cause drug interactions via CYP or P-gp.Keywords
This publication has 10 references indexed in Scilit:
- Oxycodone induces overexpression of P‐glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley ratsJournal of Pharmaceutical Sciences, 2007
- Pharmacokinetics and Variation in the Clearance of Oxycodone and Hydrocotarnine in Patients with Cancer PainBiological and Pharmaceutical Bulletin, 2007
- Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolitesClinical Pharmacology & Therapeutics, 2006
- Determination of Oxycodone and Hydrocotarnine in Cancer Patient Serum by High-Performance Liquid Chromatography with Electrochemical DetectionAnalytical Sciences, 2005
- QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMESDrug Metabolism and Disposition, 2004
- Comparison of in Vitro P-Glycoprotein Screening Assays: Recommendations for Their Use in Drug DiscoveryJournal of Medicinal Chemistry, 2003
- Does ABCG2 Need a Heterodimer Partner? Expression and Functional Evaluation of ABCG2 (Arg 482)*Drug Metabolism and Pharmacokinetics, 2002
- Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450Analytical Biochemistry, 1997
- P-glycoprotein Is Stably Inhibited by Vanadate-induced Trapping of Nucleotide at a Single Catalytic SiteJournal of Biological Chemistry, 1995
- Inorganic phosphate assay with malachite green: An improvement and evaluationJournal of Biochemical and Biophysical Methods, 1982